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Aim: To assess the etiology, underlying disease, treatment procedures, and mortality rate of lung abscesses by dividing the patients into
community-acquired lung abscess (CALA) and nosocomial lung abscess (NLA) subgroups.
Materials and methods: We reviewed and analyzed data on 62 adult cases of CALA and NLA treated during 2000–2011 at a tertiary
university hospital in Turkey.
Results: Of these 62 patients, 44 had CALA and 18 had NLA. Etiologic microorganisms were isolated in 20 of the 44 patients (45.4%)
in the CALA group and in 15 of the 18 patients (83.3%) in the NLA group. Among these patients, Staphylococcus aureus (20.0%) and
Pseudomonas aeruginosa (26.7%) were the most common microorganisms in the CALA and NLA groups, respectively. Computed
tomography-guided drainage was performed in 20 patients in the study and the abscess was cured in 17 (85%) patients. The overall
mortality rate was 12.9%. It was 4.5% and 33.3% in the CALA and NLA groups, respectively (P < 0.05).
Conclusion: Lung abscess continues to be a significant cause of morbidity and mortality despite appropriate treatment. Medical
therapy is started empirically, and so it is important to separate patients into subgroups of CLA or NLA.
Key words: Lung abscess, etiology, treatment, percutaneous drainage

1. Introduction
An abscess is defined as a collection of pus in any part
of the body (1). In the lungs, there may be single or
multiple abscesses and they are the result of a variety
of causes (1). Anaerobes comprise 60%–80% of lung
abscess etiologic pathogens, and anaerobes and
microaerophilic streptococci account for the majority of
these microorganisms (2). However, in recent years Wang
et al. reported Klebsiella pneumoniae (33%) to be the most
common etiologic pathogen in Taiwan and concluded that
the bacterial etiology of lung abscesses has changed (3).
Later, another study found that the Streptococcus species
and anaerobes were the most common pathogens in Japan
(4). However, the studies included only communityacquired lung abscesses (CALAs). A 2.4% mortality rate
has been reported for patients with community-acquired
infections, compared to a 66.7% mortality rate for patients
with nosocomial infections (5). Because of this high
mortality rate, nosocomial lung abscesses (NLAs) should
not be ignored.
In this report, we investigated 62 lung abscess patients
by etiology, underlying disease, treatment procedure, and
* Correspondence: drnuritutar@gmail.com

mortality rate by dividing the patients into CALA or NLA
subgroups.
2. Materials and methods
Data for all adults (age > 18 years) who received a diagnosis
of lung abscess between January 2000 and December 2011
at a tertiary care university hospital in Kayseri, Turkey,
were found by a computer registry system. The local
ethics committee approved the study protocol. Patients
were included in the study if they met all of the following
3 criteria: 1) symptoms of pulmonary infection, such as
fever and cough, were present; 2) a cavity with an air fluid
level in it was observed on a chest radiograph or computed
tomography (CT); and 3) documented bacteriological data
were available. Sixty-five inpatient files were identified.
Three subjects, however, were excluded for reasons such as
unsuitable data or cavitary lung carcinoma. Thus, 62 cases
were analyzed.
The diagnosis of lung abscesses was established on the
basis of clinical symptoms, laboratory data, and the findings
of imaging studies (a cavity seen on a chest radiograph
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was confirmed by a chest CT) (4). The cases were classified
into 2 groups: community-acquired infections with
clinical signs of lung abscess on admission or <48 h after
admission, and nosocomial infections with a lung abscess
developing >48 h after admission (5,6). Empyema was
diagnosed by aspiration of gross pus from the pleural space.
Cases where the aspirated pleural fluid was nonpurulent,
a positive Gram stain, or a positive culture were also
accepted as empyema. Isolation and identification of
causative organisms were carried out by the standard
procedures. Percutaneous transthoracic aspiration (PTA)
was tomography-guided. All catheters were inserted into
the patients under CT guidance. Depending on the abscess
location, the patients were scanned in supine, prone, or
oblique positions. The catheter was inserted using the
Seldinger or trocar technique. A 12-F or 14-F chest drain
catheter (Medi-tech/Boston Scientific, Watertown, MA,
USA) was used.
Contingency data were analyzed by 2-tailed chi-square
test and continuous data were analyzed by Student’s
t-test or the Mann–Whitney U test. A P value of <0.05
was considered to be statistically significant, and all
probabilities were 2-tailed. All statistical analyses were
performed with SPSS 15.0 for Windows.

3. Results
3.1. Patient characteristics and risk factors
Of the 62 patients, 44 were in the CALA group and 18 were
in the NLA group. The mean age of the patients was 51.9
± 16.9 years in total. The mean age was 50.3 ± 17.9 and
55.7 ± 14.0 years in CALA and NLA patients, respectively
(Table 1). The most common prior lung illness was
chronic obstructive pulmonary disease (COPD) and the
most common extrapulmonary condition was periodontal
disease in both groups (Table 1).
3.2. Symptoms and radiographic location
Patients had symptoms for 21.2 ± 25.7 days and 14.5 ±
19.1 days in the CALA and NLA groups, respectively.
Fever (72.7%) and cough (72.7%) were the most common
symptoms in the CALA group (Table 2). Similarly, fever
(88.9%) was the most common symptom in the NLA
group. Lesion location included the right upper lobe in
31.8% and right lower lobe in 29.5% of cases in the CALA
group (Table 2). However, the NLA group lesions were
mostly located in the right upper lobe, left upper lobe, and
left lower lobe at the same rate of 27.8%.
3.3. Diagnostic methods and results
The diagnostic methods used for bacteriology-confirmed
lung abscesses included the following in the CALA and

Table 1. Baseline characteristics and risk factors of patients.
Characteristics and risk factors
Age ± SD, years

Community-acquired infection, n (%)

Nosocomial infection, n (%)

Total, n (%)

50.3 ± 17.9

55.7 ± 14.0

51.9 ± 16.9

Male

28 (63.6)

16 (88.9)

44 (70.9)

Smoking history

21 (47.7)

9 (50.0)

30 (48.4)

41.9 ± 20.5

40.5 ± 13.8

41.5 ± 18.5

4 (9.1)

0

4 (6.5)

8 (18.2)

4 (22.2)

12 (19.3)

COPD

5 (11.4)

6 (33.3)

11 (17.7)

Bronchiectasis

3 (6.8)

1 (5.6)

4 (6.5)

Old pulmonary tuberculosis

1 (2.3)

2 (11.1)

3 (4.8)

Lung cancer

3 (6.8)

4 (22.2)

7 (11.3)

Periodontal disease

20 (45.4)

7 (38.9)

28 (43.5)

Diabetes mellitus

11 (25.0)

2 (11.1)

13 (21.0)

Malignancy

3 (6.8)

1 (5.6)

4 (6.5)

Steroid use

2 (4.5)

2 (11.1)

4 (6.5)

10 (22.7)

7 (38.9)

17 (27.4)

Total packs/years ± SD
Alcoholism
Underlying disease
None
Prior lung illness

Extrapulmonary condition

Others

256

TUTAR et al. / Turk J Med Sci
Table 2. Symptoms and radiographic location of patients.
Community-acquired infection, n (%)

Nosocomial infection, n (%)

Total, n (%)

21.2 ± 25.7

14.5 ± 19.1

19.8 ± 27.1

Fever

32 (72.7)

16 (88.9)

48 (77.4)

Cough

32 (72.7)

13 (72.2)

45 (72.6)

Sputum

29 (65.9)

14 (77.8)

43 (69.4)

Chest pain

18 (40.9)

5 (27.8)

23 (37.1)

Hemoptysis

7 (15.9)

3 (16.7)

10 (16.1)

Dyspnea

16 (36.4)

8 (44.4)

24 (38.7)

Weakness

18 (40.9)

10 (55.6)

28 (45.2)

Weight loss

6 (13.6)

4 (22.2)

10 (16.1)

Right upper lobe

14 (31.8)

5 (27.8)

19 (30.6)

Right middle lobe

3 (6.8)

1 (5.6)

4 (6.5)

Right lower lobe

13 (29.5)

1 (5.6)

14 (22.6)

Left upper lobe

6 (13.6)

5 (27.8)

11 (17.7)

Left lower lobe

5 (11.4)

5 (27.8)

10 (16.1)

Multiple and/or bilateral

3 (6.8)

1 (5.6)

4 (6.5)

Symptoms
Duration, mean ± SD, days

Radiographic location

NLA groups, respectively: sputum culture, 8 episodes
(17.7%) and 6 episodes (24.0%); bronchial lavage fluid
culture, 6 episodes (37.5%) and 7 episodes (53.8%);
pleural effusion culture, 5 episodes (41.6%) and 9 episodes
(52.9%); PTA culture, 6 episodes (37.5%) and 2 episodes
(50.0%) (Table 3). A positive blood culture result was
detected in 3 episodes (15%) in the NLA group, but there
were no positive results in the CALA group. Positive
surgical specimen cultures were detected in 1 episode each
(33.3%) in both groups.
3.4. Documented laboratory and bacterial findings
The mean white blood cell (WBC) count was 14,580 ±
5910 and 13,887 ± 8231 mL and the sedimentation rate
was 71.5 ± 30.2 and 82.7 ± 29.2 mm/h in the CALA
and NLA groups, respectively. There was no significant
statistical difference in WBC count or sedimentation
rates in patients in the CALA or NLA groups (P > 0.05).
Etiologic microorganisms were isolated in 20 of the 44
patients (45.4%) in the CALA group. Among these 20
patients, infection by a single microorganism occurred
in 16 (80.0%), infection by 2 microorganisms occurred
in 2 (10.0%), and infection by 3 microorganisms
occurred in 2 (10.0%). Staphylococcus aureus (4 patients,
20.0%) was the most common microorganism, followed

by Streptococcus pneumoniae (3 patients, 15.0%) and
Pseudomonas aeruginosa (3 patients, 15.0%) in the CALA
group. Etiologic microorganisms were isolated in 15 of the
18 patients (83.3%) in the NLA group. Among these 15
patients, infection by a single microorganism occurred in
10 (66.7%), infection by 2 microorganisms occurred in
4 (26.7%), and infection by 3 microorganisms occurred
in 1 (6.7%). Pseudomonas aeruginosa (4 patients, 26.7%)
and Nocardia spp. (3 patients, 20.0%) were the most
common microorganisms in the NLA group. Twentysix bacteria were isolated from the CALA group and 25
bacteria were isolated from the NLA group (Table 4). Of
these microorganisms, Staphylococcus aureus (4 episodes,
15.4%) and Pseudomonas aeruginosa (5 episodes, 20.0%)
were the most common organisms in the CALA and
NLA groups, respectively (Table 4). In the CALA group,
Echinococcus granulosus (n = 1) and Aspergillus spp. (n
= 1), and in the NLA group, Candida albicans (n = 3),
were isolated as nonbacterial microorganisms. Anaerobic
cultures were determined in 12 patients with 15 episodes.
Eight of them were obtained from PTA specimens, 4 from
pleural effusion, and 3 from bronchial lavage fluid culture.
There were no positive results in the anaerobic cultures.
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62 patients
(44 CALA - 18 NLA)

Medical treatment alone
(33 patients)
(22 CALA - 11 NLA)

Medical treatment
followed by percutaneous
drainage or chest tube
drainage (24 patients) (18
CALA - 6 NLA)

Medical treatment
followed by pulmonary
surgery (5 patients) (4
CALA - 1 NLA)

Percutaneous drainage
followed by pulmonary
surgery
(1 patient) (1 NLA)

Figure. Analysis of the treatment of 62 patients with lung abscess.

3.5. Treatments and outcomes
The mean hospitalization stay was 18.2 ± 10.7 and 25.4
± 14.1 days in the CALA and NLA groups, respectively,
and the difference was statistically significant (P <
0.05). Concomitant empyema was seen in 8 (18.2%)
and 5 (27.8%) patients in the CALA and NLA groups,
respectively. The treatment modalities are shown in the
Figure. Twenty-two patients (50.0%) were treated only
medically in the CALA group. Medical treatment followed
by percutaneous drainage was performed in 16 patients
(36.4%), chest tube drainage for empyema was performed
in 2 (4.5%) (the amounts of the pleural effusion of the other
6 patients with empyema were small and these patients
did not require tube drainage), and pulmonary surgery
was performed in 4 patients (9.1%) in the CALA group.
Eleven patients (61.1%) were treated only medically and
4 patients (22.2%) received medical treatment followed
by percutaneous drainage in the NLA group. Chest
tube drainage for empyema was performed in 2 patients
(11.1%) (the other 3 patients with empyema received
medical treatment and these patients did not require tube

drainage), and pulmonary surgery was also performed in
2 patients (11.1%).
Ampicillin/sulbactam; 1st-, 2nd-, or 3rd-generation
cephalosporin ± clindamycin; or metronidazole was
administered as empirical therapy in 35 (79.5%) of the 44
patients in the CALA group (Table 5). Five of the patients
(14.3%) received other chemotherapeutics because initial
antibiotic treatments were ineffective or inappropriate.
Six patients (13.6%) received fluoroquinolone, 2 patients
(4.5%) received cefoperazone/sulbactam + amikacin,
and 1 patient (2.3%) received piperacillin/tazobactam ±
clindamycin or metronidazole. There was no failure to
respond to treatment.
Fluoroquinolone was administered as empirical
therapy in 2 (11.1%) of the 18 patients in the NLA group
(Table 6). Both of them needed second-line antibiotics
and after that they died. Five patients (27.8%) received
piperacillin/tazobactam ± clindamycin or metronidazole
and 2 of them received other antibiotics because initial
antibiotic treatments were ineffective. Eleven patients
(61.1%) received carbapenem and only 3 patients needed
second-line antibiotic treatment.

Table 3. Diagnostic methods and results of patients.
Community-acquired
Diagnostic method

Episodes
studied

Nosocomial infection

Diagnostic studies, Episodes Diagnostic studies,
n (%)
studied
n (%)

Total
Episodes
studied

Diagnostic studies,
n (%)

Sputum culture

45

8 (17.7)

25

6 (24.0)

70

14 (20.0)

Bronchial lavage fluid culture

16

6 (37.5)

13

7 (53.8)

29

13 (44.8)

Pleural effusion culture

12

5 (41.6)

17

9 (52.9)

29

14 (48.2)

Blood culture

28

0

20

3 (15.0)

48

3 (6.2)

Culture of PTA specimens

16

6 (37.5)

4

2 (50.0)

20

8 (40.0)

Culture of surgical specimens

3

1 (33.3)

3

1 (33.3)

6

2 (33.3)
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Table 4. Bacteriological findings of 20 patients in CALA and 15 patients in NLA groups.
Community-acquired infection (20 patients)
Microorganisms

Nosocomial infection (15 patients)

Isolates, n

Microorganisms

Isolates, n

Staphylococcus aureus

4

Pseudomonas aeruginosa

5

Streptococcus pneumoniae

3

Acinetobacter baumannii

4

Klebsiella pneumoniae

3

Nocardia species

4

Pseudomonas aeruginosa

3

Staphylococcus aureus

3

Staphylococcus epidermidis

2

Salmonella species

3

Alpha-hemolytic Streptococcus

2

Staphylococcus epidermidis

2

Corynebacterium species

2

Streptococcus anginosus

1

Salmonella species

1

Burkholderia cepacia

1

Streptococcus cristatus

1

Serratia marcescens

1

Stenotrophomonas maltophilia

1

Citrobacter species

1

Haemophilus influenzae

1

Total

25

Gemella morbillorum

1

Proteus species

1

Streptococcus pyogenes

1

Total

26

Two patients died in the CALA group and 6 patients
died in the NLA group. The overall mortality rate was
12.9%. It was 4.5% and 33.3% in the CALA and NLA
groups, respectively. There was a statistically significant
difference in mortality rates for patients in the CALA and
NLA groups (P < 0.05). Proteus and Aspergillus spp. were
isolated in each of the 2 patients who died in the CALA
group. Both of them had diabetes mellitus. One of them
was treated with medicine alone. Medical treatment
followed by percutaneous drainage was performed in
the other patient. Six patients died in the NLA group.
Two or more pathogens were isolated in 5 patients in the
NLA group and 4 of them (80.0%) died. Death occurred
in 2 (66.7%) of 3 cases with Nocardia spp., 1 (25.0%) of
2 cases with Pseudomonas aeruginosa, 1 (50.0%) of 2
cases with Staphylococcus aureus, and both of the 2 cases
with Acinetobacter baumannii. Of these 6 patients, 5
received only medical treatment and 1 received medical
treatment followed by percutaneous drainage. Four
patients received corticosteroids ± cyclophosphamide for
idiopathic thrombocytopenic purpura, systemic lupus
erythematosus, or juvenile rheumatoid arthritis. Two
(50%) of them died and Nocardia species were isolated
in 3 of the 4 immunocompromised patients. First-line
antibiotic failure was detected in all of the exitus patients
in the CALA and NLA groups.

4. Discussion
For a review and analysis of the cases with lung abscess
treated in our hospital in the past 12 years, the 62 cases
were divided into 2 groups: community-acquired infection
and nosocomial infection. We found that the mortality
rate was significantly higher in NLA patients.
Predisposing factors responsible for lung abscess
include dental extraction, COPD, alcoholism, solid cancer,
diabetes mellitus, general anesthesia, and others (4,5). Lung
abscess can also occur as a complication of communityacquired or hospital-acquired pneumonia, especially
with Staphylococcus aureus, Staphylococcus milleri, and
Pseudomonas aeruginosa (6,7). COPD and periodontal
diseases were the most common risk factors (4,8). In the
present study, similarly, COPD was the most common
underlying prior lung illness, and periodontal diseases
were the most common extrapulmonary condition in both
of the groups separately and overall.
Many different types of specimens were used to
identify etiologic microorganisms in the lung abscesses.
In most bacteriological studies of lung abscesses,
transtracheal aspiration, protected bronchial brushing,
and PTA were the most common procedures for collection
of uncontaminated specimens (9–11). Takayanagi et al.
reported that sensitivity was 81.6% for protected specimen
brush via fiberoptic bronchoscopy (PSB), 70% for PTA,
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Table 5. First-line antibiotics, failure rate, second-line antibiotics, and outcome in community-acquired infection.
First-line antibiotics

Patients

Failure rate

Second-line chemotherapeutics

Death

Ampicillin/sulbactam; 1st-, 2nd-, 3rdgeneration cephalosporin ± clindamycin;
or metronidazole

30

5 (16.7%)

Carbapenem (n = 1), cefoperazone/sulbactam
+ amikacin (n = 1), fluoroquinolone (n = 1),
albendazole (n = 1), amphotericin b (n = 1)

2 (6.7%)

Fluoroquinolone

6

0

0

0

Piperacillin/tazobactam ± clindamycin or
metronidazole

1

0

0

0

Cefoperazone/sulbactam + amikacin

1

0

0

0

27.8% for pleural effusion, and 22% for bronchial lavage
fluid culture (4). Another report showed that sensitivity was
66% for PTA and 21% for pleural effusion (3). However, in
the present study, PSB was not used and bronchial lavage
culture sensitivity was 44.8%, PTA was 40.0%, and pleural
effusion was 48.2%. Although the sensitivities of pleural
effusion and bronchial lavage fluid culture were higher, the
sensitivity of PTA was lower than in the other studies.
We also reviewed the etiologic agents in the study.
Staphylococcus aureus and Pseudomonas aeruginosa were
the most common microorganisms in the CALA and NLA
groups, respectively. Mori et al. also examined patients by
dividing them into 2 groups, CALA and NLA (5). They
reported that Staphylococcus aureus was the most common
etiologic pathogen of CALA, and Pseudomonas aeruginosa
and Klebsiella spp. were the most common pathogens of
NLA, which was similar to our results except for Klebsiella.
It is known that alcoholism is an important risk factor
associated with Klebsiella pneumoniae lung abscesses (12).
In our study, the alcoholism rate was very low compared
with other reports (4,12) and this may be the reason that
Klebsiella pneumoniae was isolated less than the others.

Pulmonary nocardiosis is an important cause of
opportunistic infection in immunocompromised patients.
However, it is not so easy to diagnose nocardiosis. A high
degree of clinical suspicion is required, and communication
with the microbiology laboratory is paramount due to
the slow growth in standard cultures. Early diagnosis is
important in nocardiosis because of the high mortality
rate (11%–48%) (13–15). In the present study, 4 patients
received corticosteroids ± cyclophosphamide, and
Nocardia species were isolated in 3 of them. Furthermore,
death occurred in 2 (66.7%) of these 3 cases. It should
also be emphasized that Acinetobacter baumannii, which
is the most frequent pathogen for ventilator associated
pneumonia (16), was detected in 2 patients with lung
abscesses and both of them died.
Ampicillin + sulbactam and clindamycin ±
cephalosporin are both well tolerated and have proven
to be equally effective in the treatment of aspiration
pneumonia and lung abscesses (17). Takayanagi et
al. reported that ampicillin/sulbactam and 2nd-, 3rd, or 4th-generation cephalosporin, with or without
clindamycin, were administered as empirical therapy,

Table 6. First-line antibiotics, failure rate, second-line antibiotics, and outcome in nosocomial infection.
First-line antibiotics

Patients

Failure rate

Second-line antibiotics

Death

Fluoroquinolone

2

2 (100%)

Cefoperazone/sulbactam + amikacin (n = 1),
carbapenem (n = 1)

2 (100%)

Piperacillin/tazobactam ±
clindamycin or metronidazole

5

2 (40%)

Fluoroquinolone + amikacin (n = 1), cefoperazone/
sulbactam + colistin (n = 1)

2 (40%)

Carbapenem

11

3 (27.3%)

Fluoroquinolone + colistin + linezolid (n = 1),
ceftriaxone + trimethoprim sulfamethoxazole (n = 1),
liposomal amphotericin B (n = 1)

1 (9.1%)
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and the failure rate was 11.9% and 7.1%, respectively (4).
Similarly, in the present study, ampicillin/sulbactam; 1st-,
2nd-, or 3rd-generation cephalosporin ± clindamycin; or
metronidazole were administered as empirical therapy
in 35 patients (79.5%), and the failure rate was 14.3% in
CALA. However, empirical therapy was different in NLA.
The preferred agents for empiric therapy for nosocomial
pneumonia (late onset disease or multidrug resistance)
are antipseudomonal cephalosporin and antipseudomonal
carbapenem or β-lactam/β-lactamase inhibitor plus
antipseudomonal fluoroquinolone (6). Carbapenems
possess a broad spectrum of antibacterial activity
that makes them suitable for the empiric treatment of
nosocomial pneumonia in certain situations (18). In the
present study, carbapenems also had the lowest failure rate
(27.3%) in the NLA group.
In recent years, CT-guided percutaneous catheter
drainage has been found to be a useful and safe procedure
for the treatment of lung abscesses (19). The success rate
was reported to be 79%–100%, and CT-guided drainage
should be considered as the first therapeutic choice in
most patients with lung abscess who do not respond to
medical therapy as an alternative to open surgery (19–22).
In our hospital, similarly, when lesions do not respond
to antibiotics, CT-guided drainage is applied. CT-guided
drainage was performed in 20 patients in our study. The
abscess was cured in 17 (85%) patients, which is consistent
with other reports.

Mortality from lung abscess was reported to be from
1.0% to 20.0% in twentieth century studies (3,4,8,23).
However, these studies included only CALA patients. Mori
et al. reported that the mortality rate was 66.7% in NLA
patients (5). In the present study, the mortality rate was
4.5% and 33.3% in CALA and NLA, and the difference
was statistically significant (P < 0.05). The main difference
between these 2 groups is the need to be especially careful
with NLA patients.
One limitation of the present study is that it was
retrospective. A second limitation is that the number of
anaerobic cultures was not enough. Anaerobic cultures
were determined in 12 patients (19.3%) with 15 episodes,
and there were no positive results. The reason for this is
probably that the samples were not taken or protected
properly. In addition, PSB is not commonly used in our
hospital, so there were no studied specimens to investigate.
In conclusion, lung abscess continues to be a significant
cause of morbidity and mortality despite appropriate
antibiotic therapy and invasive methods. Mortality was
dramatically higher in the NLA group. Medical treatment
is started empirically, and so it is important to separate
patients into subgroups of CLA or NLA. If the response to
medical therapy is poor, percutaneous drainage should be
the first choice of treatment.
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